Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 12 of the 51 sources its claims cite were checked for support.
Abstract
C3 deficiency protects against hippocampal neurodegeneration and cognitive decline in aged APP/PS1 mice despite abundant Aβ plaques.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our previous results (5), C3 KO mice had significantly more synaptic puncta than WT mice.”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Results > Partial protection against age-related hippocampal synaptic degeneration in APP/PS1;C3 KO mice
What the sources say
- Partly supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 sourceExperimental — accuracy not yet measured
Our copy does report significantly higher synaptic puncta density in C3 KO vs WT mice, but only with age and region bounds the citing sentence drops: at P30 there were no genotype differences, at 4 months only presynaptic Vglut2-IR puncta differed (p = 0.0347) with no difference in Homer1 or colocalization, and the full increase (Vglut2 p = 0.002, Homer1 p < 0.0001, colocalization p = 0.0109) appears at 16 months in HC CA3-SR, with similar effects in DG-SM and V1 but explicitly no differences in CA1 (Results, 'Complement-deficient mice do not display age-related synapse loss'; Fig. 2 legend, 'C3 deficiency in neurodegeneration'). The unqualified statement 'C3 KO mice had significantly more synaptic puncta than WT mice' therefore overstates the source by omitting the aged-timepoint and region-specific qualifiers. The supporting evidence for the direction of the effect (and corroborating Golgi spine-density and Western blot synaptic-marker increases at 16 months) is present in the same sections. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactive microglia (8, 9, 11, 12)”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [8] Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA, Temporal accrual of complement proteins in amyloid plaques in Down’s syndrome with Alzheimer’s disease. Am J Pathol 156, 489– 499 (2000). 10666378 PMC1850044 source
The paper states that classical complement activation has been observed in AD brain and that compacted amyloid plaques in AD are often associated with activated microglia and complement proteins. Its Discussion further links abundant complement proteins in compacted plaques with activated microglia in AD-type lesions. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Not checked yetcites [9] Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM, Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer’s disease. Res Immunol 143, 617– 620 (1992). 1455052 source
- Not checked yetcites [11] Veerhuis R, Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8, 34– 58 (2011). 21143154 source
- Not checked yetcites [12] Tenner AJ, Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22, 849– 861 (2001). 11754992 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently demonstrated that C3-deficiency spared age-dependent synaptic and neuronal loss in a region-specific manner, and protected against cognitive impairment in normal aging of C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Introduction
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The section 'Complement-deficient mice do not display age-related HC neuron loss' (p. ~ Results) states that age-dependent, region-specific synapse and neuron loss seen in WT C57BL/6J mice (CA3-SR, DG-SM reduced; CA1 spared) was rescued in aged male C3 KO mice, who had more synaptic puncta, higher SYP density and synaptic protein levels, higher LTP and more CA3 neurons. The section 'Complement C3-deficient mice do not display age-dependent behavioral deficits' states that C3 deficiency significantly protected mice against age-related cognitive decline, and the Summary ('C3 deficiency in neurodegeneration') reiterates that these age-related effects were spared in C3 KO mice. All elements of the citing sentence — C3-deficiency, sparing of age-dependent synaptic and neuronal loss in a region-specific manner, protection against cognitive impairment, and normal aging of C57BL/6 mice — are carried by our copy. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previously, we reported an age-dependent loss of CA3 neurons in 16 month-old C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The Results section, “Complement-deficient mice do not display age-related HC neuron loss,” reports significantly fewer CA3 neurons in 16-month-old wild-type mice than at P30. The paper identifies the wild-type mice as C57BL/6J. The 16-month versus 4-month comparison was not significant, so the demonstrated loss is relative to P30. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“16-month-old APP/PS1;C3 KO mice performed significantly better on a learning and memory task than APP/PS1 mice, despite having more cerebral Aβ plaques.”
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
“Reversal learning in APP/PS1;C3 KO mice was similar to that of WT mice and C3 KO mice, and was significantly better than that of APP/PS1 mice on Days 4 and 5”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
48 more claims
Create a free account to see all 111 claims and to verify the 39 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Actually, inflammation even happens earlier than protein aggregation.”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, IFN-γ-induced C3 expression in an amyloidogenic mouse model reduced plaque load but resulted in increased loss of synapses and cognitive dysfunction [152, 284].”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous reports suggesting that plaque morphology, rather than total amyloid burden, may be a key factor in neurotoxicity and disease progression and suggest that this could be an important role for plaque‐associated PLCγ2 expressing microglia (Casali et al. 2020; Shi et al. 2017; Yuan et al. 2016).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Shi et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent data indicate that microglia and astrocytes coordinate their functions in many ways, both in the healthy and diseased brain [14–21].”
From Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
“Recently, Hong et al. reported similar Aβ oligomer-induced, complement-mediated and microglia-dependent synaptic loss in young, pre-plaque AD mice that was rescued by the genetic deletion of C1q or C3, or by treatment with a C1qa blocking antibody (8).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > References
“10. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712– 716 (2016). 27033548 PMC5094372”
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Self-citationMicroglia promote learning-dependent synapse formation through brain-derived neurotrophic factor
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., Lafaille, J. J., Hempstead, B. L., Littman, D. R., & Gan, W.-B. (2013) · Cell · doi:10.1016/j.cell.2013.11.030 · Cited by 2,599 · cited 1×
“Furthermore, mice deficient in BDNF in microglia have deficits in learning andhippocampal synapse formation, indicating thatmicroglial BDNF signaling plays an important role in hippocampal function (60).”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Self-citationRole of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza-Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 707
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
“C3-deficient mice show protection from neurodegeneration 461 , spine loss 452 , and excessive microglial cell-mediated synapse loss 452 and C3aR is a modulator of microglial function 451,462 .”
Self-citationDeep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression
Bai, B., Wang, X., Li, Y., Chen, P.-C., Yu, K., Dey, K. K., Yarbro, J. M., Han, X., Lutz, B. M., Rao, S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.015 · Cited by 565
“Further genetic crossing analysis support that C3 deficiency protects the mice against synapse loss and memory decline in the APP/PS1 mice (Shi et al., 2017).”
BackgroundInflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532
Litvinchuk, A., Wan, Y.-W., Swartzlander, D. B., Chen, F., Cole, A., Propson, N. E., Wang, Q., Zhang, B., Liu, Z., & Zheng, H. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.031 · Cited by 523
Novel mechanisms and functions of complement
Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2017) · Nature Immunology · doi:10.1038/ni.3858 · Cited by 488
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Wu, T., Dejanovic, B., Gandham, V. D., Gogineni, A., Edmonds, R., Schauer, S., Srinivasan, K., Huntley, M. A., Wang, Y., Wang, T.-M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.060 · Cited by 466
Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection
Adaikkan, C., Middleton, S. J., Marco, A., Pao, P.-C., Mathys, H., Kim, D. N.-W., Gao, F., Young, J. Z., Suk, H.-J., Boyden, E. S., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.011 · Cited by 469
New insights into the immune functions of complement
Reis, E. S., Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0168-x · Cited by 470
Astrocytes and microglia: In sickness and in health
Vainchtein, I. D., & Molofsky, A. V. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.01.003 · Cited by 450
Microglia modulate neurodegeneration in Alzheimer’s and Parkinson’s diseases
Bartels, T., De Schepper, S., & Hong, S. (2020) · Science · doi:10.1126/science.abb8587 · Cited by 412
Self-citationTLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
“C3 deficiency ameliorates age-dependent loss of synapses and neurons, and cognitive deficits in aged APP/PS1 mice although it increases cerebral Aβ deposits (191).”
BackgroundComplement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Bisht, K., Sharma, K., & Tremblay, M.-È. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.05.003 · Cited by 360
“1) still devoid of plaques, as well as during normal aging in wild-type mice (Shi et al., 2017).”
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Microglia-Mediated Synapse Loss in Alzheimer's Disease
Rajendran, L., & Paolicelli, R. C. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1136-17.2017 · Cited by 355
“Indeed, several of the risk genes associated with AD, such as ApoE and TREM2, seem to be expressed in, or depend on, microglia for their expression (Efthymiou and Goate, 2017).”
BackgroundInfluentialClinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model
Reichenbach, N., Delekate, A., Plescher, M., Schmitt, F., Krauss, S., Blank, N., Halle, A., & Petzold, G. C. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809665 · Cited by 343
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“It is becoming increasingly clear that microglia and immune signaling may not just be secondary players in disease processes but actually contribute to synaptic and neuron loss and buildup of pathogenic proteins even at the earliest stages of disease (Figure 2) (Hong et al., 2016; Shi et al., 2017; Sosna et al., 2018).”
BackgroundSelf-citationNeuron-glia signaling in synapse elimination
Wilton, D. K., Dissing-Olesen, L., & Stevens, B. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050306 · Cited by 332
Self-citationThe clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease
Bairamian, D., Sha, S., Rolhion, N., Sokol, H., Dorothée, G., Lemere, C. A., & Krantic, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00522-2 · Cited by 314
“Genetic deletion of C3 protected hippocampal synapses and cognition in both WT and transgenic mice despite increasing plaque deposition in the APP/PS1 mouse model [66, 67].”
BackgroundSelf-citationPhagocytosis in the Brain: Homeostasis and Disease
Galloway, D. A., Phillips, A. E. M., Owen, D. R. J., & Moore, C. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00790 · Cited by 307
A1/A2 astrocytes in central nervous system injuries and diseases: Angels or devils?
Fan, Y.-Y., & Huo, J. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105080 · Cited by 304
The state of complement in COVID-19
Afzali, B., Noris, M., Lambrecht, B. N., & Kemper, C. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00665-1 · Cited by 293
Microglial phagocytosis of neurons in neurodegeneration, and its regulation
Butler, C. A., Popescu, A. S., Kitchener, E. J. A., Allendorf, D. H., Puigdellívol, M., & Brown, G. C. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15327 · Cited by 295
“During ageing of mice and rats, there is a slow but progressive loss of synapses and neurons (Morterá & Herculano- Houzel, 2012; Shi et al., 2015, 2017).”
BackgroundThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
“This has also been supported by observations in multiple AD mouse models [86, 131, 132].”
BackgroundResultFlores, J., Noël, A., Foveau, B., Lynham, J., Lecrux, C., & LeBlanc, A. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06449-x · Cited by 287
De Schepper, S., Ge, J. Z., Sierksma, A., Crowley, G., Ferreira, L. S. S., Garceau, D., Toomey, C. E., Sokolova, D., Rueda-Carrasco, J., Shin, S.-H., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01257-z · Cited by 295
“In line with our data, this suggests that the timing of phagocytic activity in different stages of disease might be critical to determine the protective versus detrimental nature of the outcome 15,69,70 .”
Self-citationNeuroinflammation after surgery: from mechanisms to therapeutic targets
Yang, T., Velagapudi, R., & Terrando, N. (2020) · Nature Immunology · doi:10.1038/s41590-020-00812-1 · Cited by 274
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“Aβ oligomers increase the expression of the complement protein C3 in microglia, which marks synapses and promotes microglial recruitment, leading to synapse elimination (Shi et al., 2017).”
BackgroundInfluentialMicroglia and the brain: Complementary partners in development and disease
Hammond, T. R., Robinton, D., & Stevens, B. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060509 · Cited by 288
Self-citationProteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
“Deleting C3 in the AD (APP/PS1) mice was shown to rescue synapse loss and memory decline [178].”
BackgroundThe biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
“Further, down-regulating C3 in animal models of AD showed a decreased frequency of neurodegenerative phenomena [291,292].”
BackgroundKopec, A. M., Smith, C. J., Ayre, N. R., Sweat, S. C., & Bilbo, S. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06118-z · Cited by 258
Losurdo, M., Pedrazzoli, M., D'Agostino, C., Elia, C. A., Massenzio, F., Lonati, E., Mauri, M., Rizzi, L., Molteni, L., Bresciani, E., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0327 · Cited by 260
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 239
“also exhibited better performance on a learning and memory task [155].”
BackgroundGuttikonda, S. R., Sikkema, L., Tchieu, J., Saurat, N., Walsh, R. M., Harschnitz, O., Ciceri, G., Sneeboer, M., Mazutis, L., Setty, M., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00796-z · Cited by 243
Propson, N. E., Roy, E. R., Litvinchuk, A., Köhl, J., & Zheng, H. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140966 · Cited by 258
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frere, S., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 237
Gamma Entrainment: Impact on Neurocircuits, Glia, and Therapeutic Opportunities
Adaikkan, C., & Tsai, L.-H. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2019.11.001 · Cited by 242
Lipid and Lipoprotein Metabolism in Microglia
Loving, B. A., & Bruce, K. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00393 · Cited by 255
Roy, E. R., Chiu, G., Li, S., Propson, N. E., Kanchi, R., Wang, B., Coarfa, C., Zheng, H., & Cao, W. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.018 · Cited by 236
Microglia-neuron crosstalk: Signaling mechanism and control of synaptic transmission
Marinelli, S., Basilico, B., Marrone, M. C., & Ragozzino, D. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.017 · Cited by 233
Microglia in Brain Development, Homeostasis, and Neurodegeneration
Bohlen, C. J., Friedman, B. A., Dejanovic, B., & Sheng, M. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-112618-043515 · Cited by 212
Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion
Zhang, L.-Y., Pan, J., Mamtilahun, M., Zhu, Y., Wang, L., Venkatesh, A., Shi, R., Tu, X., Jin, K., Wang, Y., et al. (2020) · Theranostics · doi:10.7150/thno.35841 · Cited by 217
“The complement proteins C1q and C3 mediate synapse elimination during development and neurodegeneration through C3-dependent microglia phagocytosis [18-20].”
BackgroundThe role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan
Tay, T. L., Béchade, C., D’Andrea, I., St-Pierre, M.-K., Henry, M. S., Roumier, A., & Tremblay, M.-E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 216
“Additionally, C3 deficient APP/PS1 mice displayed increased numbers of Vglut2-GluR1 puncta and protein levels of various synaptic markers during aging in the hippocampus, where IBA1-positive microglia recovered surveillant morphologies near plaques (Shi et al., 2017).”
BackgroundRostami, J., Mothes, T., Kolahdouzan, M., Eriksson, O., Moslem, M., Bergström, J., Ingelsson, M., O’Callaghan, P., Healy, L. M., Falk, A., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02158-3 · Cited by 239
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Carpanini, S. M., Torvell, M., & Morgan, B. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00362 · Cited by 207
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Lecca, D., Jung, Y. J., Scerba, M. T., Hwang, I., Kim, Y. K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S., Liu, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12610 · Cited by 218
Stroke subtype-dependent synapse elimination by reactive gliosis in mice
Shi, X., Luo, L., Wang, J., Shen, H., Li, Y., Mamtilahun, M., Liu, C., Shi, R., Lee, J.-H., Tian, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27248-x · Cited by 212
Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function
Spiteri, A. G., Wishart, C. L., Pamphlett, R., Locatelli, G., & King, N. J. C. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02384-2 · Cited by 244
“Furthermore, complement activation, which is important for microglial phagocytosis, can exacerbate synaptic loss [152, 284, 291] and contribute to memory loss and cognitive decline [75] (Table 5).”
BackgroundThe Role of Complement in Synaptic Pruning and Neurodegeneration
Gomez-Arboledas, A., Acharya, M. M., & Tenner, A. J. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s305420 · Cited by 197
Synapse pathology in Alzheimer’s disease
Griffiths, J., & Grant, S. G. N. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.05.028 · Cited by 198
Peripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
“A recent study testing effects of C3 deficiency in the APPPS1 model emphasised the dual-edged nature of complement; C3deficient mice showed an increase in amyloid plaque load, in agreement with other studies, but were nevertheless protected against cognitive decline [58].”
ResultTherapeutic Targeting of the Complement System: From Rare Diseases to Pandemics
Garred, P., Tenner, A. J., & Mollnes, T. E. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000072 · Cited by 208
“There is increasing evidence for a role for complement in Alzheimer disease (Hong et al., 2016; Hernandez et al., 2017; Shi et al., 2017) and other neurodegenerative and neurologic disorders, such as amyotrophic lateral sclerosis (Lee et al., 2018; Parker et al., 2019), epilepsy (Chu et al., 2010;…”
BackgroundMeilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210
“…underscored that the Trem2-dependent microglial activation around plaque is protective for neurons and is distinct from microglia-mediated, complement-mediated activities that contribute to synapse loss in -amyloid models (Fonseca et al., 2004; Hong et al., 2016; Shi et al., 2017; Wu et al., 2019).”
BackgroundReactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease
Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 177
“Similarly, knockdown of C3 preserved synaptic density and improved cognition in APP/PS1 mice, despite enhanced amyloid plaque load under these conditions (Shi et al., 2017).”
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
“loidogenic models, indicating that this clearance mechanism might be a double-edged sword [64, 65].”
BackgroundVilalta, A., & Brown, G. C. (2018) · The FEBS Journal · doi:10.1111/febs.14323 · Cited by 174
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
Van Bulck, M., Sierra-Magro, A., Alarcon-Gil, J., Perez-Castillo, A., & Morales-Garcia, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030719 · Cited by 178
Loss of microglial SIRPα promotes synaptic pruning in preclinical models of neurodegeneration
Ding, X., Wang, J., Huang, M., Chen, Z., Liu, J., Zhang, Q., Zhang, C., Xiang, Y., Zen, K., & Li, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22301-1 · Cited by 180
Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., Jain, P., Dunnett, S., Sohrabi, S., Fjeldstad, M. P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.044 · Cited by 179
“The complement system has been previously shown to be involved in phagocytosis of synapses in plaque- and tangle-bearing models separately (Dejanovic et al., 2018; Hong et al., 2016; Litvinchuk et al., 2018; Shi et al., 2017).”
BackgroundMicroglia as hackers of the matrix: sculpting synapses and the extracellular space
Crapser, J. D., Arreola, M. A., Tsourmas, K. I., & Green, K. N. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00751-3 · Cited by 178
Zhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168
Functional dissection of astrocyte-secreted proteins: Implications in brain health and diseases
Jha, M. K., Kim, J.-H., Song, G. J., Lee, W., Lee, I. K., Lee, H., An, S. S. A., Kim, S., & Suk, K. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.003 · Cited by 167
“Recently, Shi et al. (2017) have reported that a deficiency of complement C3 protects against neurodegeneration in aged and plaque-rich APP/PS1 mice via the modulation of Ab plaque pathology, glial response to plaques, and neuronal dysfunction in the brain (Shi et al., 2017).”
BackgroundTargeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 193
“It is also worth noting that amyloidosis mouse models have increased amyloid-plaque load when the C3 gene is deleted 21,225 , which is not seen with C1q-deficient mice 226,227 , suggesting a classical pathway-independent function of C3 in plaque suppression.”
Haure-Mirande, J.-V., Audrain, M., Ehrlich, M. E., & Gandy, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00552-w · Cited by 159
Krukowski, K., Chou, A., Feng, X., Tiret, B., Paladini, M.-S., Riparip, L.-K., Chaumeil, M. M., Lemere, C., & Rosi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123753 · Cited by 141
“Deletion of C1q was shown to decrease synapse loss in aged Tg2576 or APP/PS1 mice [32], while C3 deletion was shown to rescue both synapses loss and learning and memory deficits in aged plaque-rich APPswe/PSdE9 transgenic mice [15].”
BackgroundSelf-citationCD4+ effector T cells accelerate Alzheimer’s disease in mice
Machhi, J., Yeapuri, P., Lu, Y., Foster, E., Chikhale, R., Herskovitz, J., Namminga, K. L., Olson, K. E., Abdelmoaty, M. M., Gao, J., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02308-7 · Cited by 143
“Co-expression of both pre- and post-synaptic proteins is essential for neuroplasticity, and therefore alteration of either protein level affects memory [6, 47].”
BackgroundThe amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
Drummond, E., Kavanagh, T., Pires, G., Marta-Ariza, M., Kanshin, E., Nayak, S., Faustin, A., Berdah, V., Ueberheide, B., & Wisniewski, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01356-1 · Cited by 137
Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration
Henstridge, C. M., Tzioras, M., & Paolicelli, R. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00063 · Cited by 143
Zhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
“…to modestly raised CCP activity and moderate loss of excitatory synapses in Nptx2 KO or C4-overexpressing mice, C1q and downstream complement components are highly up-regulated in many chronic neurodegenerative diseases, including AD, FTD, and Huntington ’ s disease ( 7 – 9 , 11 , 13 , 36 , 47 ).”
BackgroundMicroglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
C3 ‐dependent effector functions of complement
Zarantonello, A., Revel, M., Grünenwald, A., & Roumenina, L. T. (2022) · Immunological Reviews · doi:10.1111/imr.13147 · Cited by 173
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease
Ghosh, A., Comerota, M. M., Wan, D., Chen, F., Propson, N. E., Hwang, S. H., Hammock, B. D., & Zheng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1206 · Cited by 136
Complement dysregulation in the central nervous system during development and disease
Lee, J. D., Coulthard, L. G., & Woodruff, T. M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101340 · Cited by 128
Rahman, M. R., Islam, T., Zaman, T., Shahjaman, M., Karim, M. R., Huq, F., Quinn, J. M. W., Holsinger, R. M. D., Gov, E., & Moni, M. A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.07.018 · Cited by 136
Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R., Mejias-Ortega, M., Fernandez-Valenzuela, J. J., Nuñez-Diaz, C., Caceres-Palomo, L., Vegas-Gomez, L., Sanchez-Mejias, E., Trujillo-Estrada, L., Garcia-Leon, J. A., Moreno-Gonzalez, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 129
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“However, chronic microglial activation may be associated with production of neurotoxic inflammatory cytokines and reactive oxygen species (31), and microglia have been suggested to phagocytose synapses under pathological conditions (32,33); therefore, they could exert deleterious effects that contribute to disease pat…”
P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer’s disease model
Reichenbach, N., Delekate, A., Breithausen, B., Keppler, K., Poll, S., Schulte, T., Peter, J., Plescher, M., Hansen, J. N., Blank, N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171487 · Cited by 131
“…chronic MRS2179 treatment on hippocampal CA1 synapses, we performed high-resolution confocal microscopy analysis of the colabeled pre- and postsynaptic markers synaptophysin and Homer1—i.e., synaptic puncta (Shi et al., 2017)—in brain sections from APP PS1 mice and age-matched WT littermates (Fig.”
BackgroundMethodCong, Q., Soteros, B. M., Wollet, M., Kim, J. H., & Sia, G.-M. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0672-0 · Cited by 126
Differential contribution of microglia and monocytes in neurodegenerative diseases
Baufeld, C., O’Loughlin, E., Calcagno, N., Madore, C., & Butovsky, O. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1795-7 · Cited by 123
“Microglia are responsible for complement-mediated synaptic loss (Hong et al. 2016), which can be rescued by deleting complement factors C1q, C3, or CR3 in a mouse model of AD (Maier et al. 2008; Shi et al. 2017).”
BackgroundRueda‐Carrasco, J., Sokolova, D., Lee, S., Childs, T., Jurčáková, N., Crowley, G., De Schepper, S., Ge, J. Z., Lachica, J. I., Toomey, C. E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022113246 · Cited by 122
“…(Stevens et al , 2007; Schafer et al , 2012) is reactivated in a region-specific manner to mediate synaptic dysfunction and loss (Hong et al , 2016; Lui et al , 2016; Shi et al , 2017; Dejanovic et al , 2018; Vukojicic et al , 2019; Wu et al , 2019; Gratuze et al , 2020; Werneburg et al , 2020).”
BackgroundSelf-citationC3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa
Silverman, S. M., Ma, W., Wang, X., Zhao, L., & Wong, W. T. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190009 · Cited by 119
Wang, J., Chen, H.-S., Li, H.-H., Wang, H.-J., Zou, R.-S., Lu, X.-J., Wang, J., Nie, B.-B., Wu, J.-F., Li, S., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.12.019 · Cited by 122
Synaptic Elimination in Neurological Disorders
Cardozo, P. L., de Lima, I. B. Q., Maciel, E. M. A., Silva, N. C., Dobransky, T., & Ribeiro, F. M. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603170511 · Cited by 115
Systemic inflammation linking chronic periodontitis to cognitive decline
Wang, R. P., Ho, J. Y. S., Leung, W. K., Goto, T., & Chang, R. C. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.07.002 · Cited by 141
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Cell Death and Neurodegeneration
Andreone, B. J., Larhammar, M., & Lewcock, J. W. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a036434 · Cited by 132
“Consistent with this idea, genetic ablation or pharmacological inhibition of molecular components of complement protects against neuron loss in several mouse models, arguing that microglia contribute to neuronal cell death via synapse phagocytosis (Fonseca et al. 2004; Hong et al. 2016; Shi et al. 2017; Dejanovic et a…”
Background
Metadata
- Authors
- Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Lemere, Cynthia A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-31
- Volume
- 9
- Issue
- 392
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6936623
- OpenAlex
- W2618794795
- Semantic Scholar
- 9b3f6a14369dd65bfc394e92ccb26bd20b83ccd0
- Cited by
- 593
- References
- 70
- Citations by year
- 2026: 47 · 2025: 72 · 2024: 75 · 2023: 71 · 2022: 66 · 2021: 88 · 2020: 64 · 2019: 50 · 2018: 43 · 2017: 17
- FWCI
- 35.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (award298479, R21 AG044713)
- BrightFocus Foundation (award298478, A2016425F)
- Fidelity Biosciences (award298481, (F-PRIME), award298470, F-PRIME)
- Edward R and Anne G Lefler (award298482, Fellowship)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- complement C3, complement system, neurodegeneration, Alzheimer's disease, APP/PS1 mice, amyloid plaques, microglia, synaptic loss, neuronal loss, aging, glial response
- MeSH terms
- Aging, Animals, Astrocytes, Complement C3, Gliosis, Hippocampus, Mice, Inbred C57BL, Nerve Degeneration, Solubility, Synapses, Cytokines, Amyloid beta-Protein Precursor, Mice, Knockout, Presenilin-1, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.